|AHFS/Drugs.com||International Drug Names|
|Bioavailability||High (Tmax = 2–3 hours)|
|Onset of action||1–1.5 hours|
|Excretion||Biliary (95%), renal (5%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||527.634 g/mol g·mol−1|
|3D model (JSmol)|
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
- Allergy to sulfonylureas or sulfonamides
- Diabetes mellitus type 1
- Diabetic ketoacidosis
- Patients that underwent removal of the pancreas
- Acute porphyria
- Severe liver disease accompanying with liver insufficiency
- Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required
- Pregnancy or breastfeeding
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients suffering from kidney disease and diabetic nephropathy.
- "Glurenorm (gliquidone) 30 mg Tablets, for Oral Use. Full Prescribing Information". Russian State Register of Medicinal Products (in Russian). Boehringer Ingelheim. Retrieved 12 July 2016.